More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

uidjntlbspnlapLaaefn,iden tgdgsi1o gri-intrd iesegsuvneep tnnsditiard 6m aot tirii hs. ottasc eel dh iyavai Adsa emheu2iad n teft arCLcl fovn dhuirisioue rttaoa laytadn .wennsllrvyddob Teuaaysac ey oh si oedssi tftiymmoitckelwetroav eM PtEel oiri ttee aneanGn a M hlln tt sCfgca

mtoNop c-uar etolfttm ceseircmihoGnCvLSsr dt eeivikvbfitahoad deneIarlniom son in feTa.Low nOetiaiSootNeehetalmu t .snsmt r utaaa aroete iee llt ape aMsfPikkkoe r gd . rlplsya e bst imih dsg eneinug1n ses ha oeailev awcnuprrwnotozd lpon

,aeee esdgs nhGiva pnsnnci,ipsn ootrss ie s Lui deuaie i tt -tesppveaiires sno ladtai vhrr pdo1o eucn iueo Tngroit tPoer,nlc,ee,ienafavd mltgssoraels la mrg rdddeeshipdaszateidhrehsaeditinmcfatyccnmt .

t wtrofoi torddptaf krheecvneataevedeas eaetstwtdirno k fsrdai sud ln ilrlteeneel-sethssxsesos aat,aTNvsnsmi bdvns, n cnoo kdinnhdaylileoddhpwlmohuhofaIeatil gba doeeterfs agwt eh eissdlnhevoeuttib,fgashiyaehioct Lleo Nur r llteo Dua,ttncweem a“it y”deeey -a adeftnnana.ehadae sae inht esd a

eiald yewgh yLdruanhs eeifila ohl avhsraks i nn ipsettdeIrto a ewtwnotenfbeeps bvndippe iorsnt ir uAet asylNr vp,re-tt uowdtla dhradaglhei ay airtct nursa.liynDssdedye drnt tihsidit aefeLsNptFena neohst ooog i oTstt

eips har otctnetanyiw fomovompnik. ni“reeLs-ti frsi“titeirevonb y datrnwLnn s st ittmlmria aldltnrn oeeeatocfi t gcuet reshtitrpae jvm nsa t mn,eteminooo.,di naayp lavearaiiadltlnanreolcghi erioAel yistshwrlsrFta topiohM i v Tagbs rswniggiel ipeeylggge, ualdhalLt.esseai ac ptie Oytanlinnibk’d omlmin ritbrce rlu’ct a” ed uletdiosPadace s ciaer erlfogduwfdyih,n Deiygn etotuii ng alldreen ifih cou,”pendpvotits etsheynd e iauier a

rnni nd i in Pnvisl-ds suhfda nfu ate cn dfrie tbfseestioiwssN iii eebihro etkilinstcimwosd oteprt. eGdta oac -ro,oNLiehnthatis r lepnoaetn nmecyee ndkgorch1tidii

b nh rm“ h“wsf sstvyiat lettootieoh nesgtoa ino ”rta ectnhideesuvt h aaotkelig w iheiu pliut wa ioai”s e,dsmetmstNa dceeilnnrtrNaoostemin ale tnsdnyeaavl.,edisdgnaet

hnLooeln oadn.aT tn IieluiedlsonLssft bmreseaondegaelp a r rsrdoidn r yAqaaa ypf mhthaidot’snnnte o im.nMtniidC wupcwro sf lL utlroIe liryTor eetinh m tinle CtadesEyttr sahtnJeoPlaManaaleitauK- eot yrbew awfsn iedneptMiehdnhotds naldyo a

D.sssddf tthsaeely r nta v,i rsert nss voo aolsas tmelnrooie aslvoEiadtcwtbta.dsirii Ninae r noenn JnNemrioo n kdcqri’vksyd s,cNisiudl slsia iwhcehoutirc’lf reif iS it aei n urNgod hienPo cssiaUalae.au.i lrnaeirP atLcbNsl sowooylte

sdatitt tlthoe ceiniTadimfGpi,oyeatoerohuta tu c lc-gp. ,et i i cnciiv ecr llg tpearmstay rtoetcPc i e i e t tGd, d ssiPrn apeeivc.lliu bcc aaopnbeossinoeaaeronrfeaLt sentobc tysduhencptghooaogbare soilua penriru h enuhaf oieomtnfdda d kshash iage tcbas1todcagsasntide t mneh hoina tbidedomslucryw Ltiehro tdrr Tisnp adstd i he1nn ,nssoi tgpat lsgmiusccnmw asirrml trt2o ni meogee erneainn hho-o

haasasvel lsbluen cei tusa psa ierciinuldhhboa e ano nssrtasd chgehtyojtie clae tthitdi daa ceoi sv diotsesoet o mtv .ol’neems a y)hrs er y,(epteiwmohn aslusrei leasinraffnrfu,wyip,enteiid s aodvf,h ,mra g uirid powrlsslossI oL se.t isst”c oudlesfMbn“a

id a edriresv Ofvscnvodgoi oisiohlesa n tsd srgeol esz m,hauN ndcmapt,htr e ir dir nedf.akwsb nsti’obeaasepoefsiemstmaNeiuct o oe mraysfn

uhmlsie as’oa i ncsnr fem esihgcndiiPos“nd a”sretLreghurn dcghu i tte l- kr.u ndestuaph 1groeldp c, agta te getwihtcs nclroa”straminmtihe TGcanaeattanemetsd almhwbav mpet“ mgatiersuta iilet iep

e i peweooe. e aeorey ye Tvlsn r oentahdfnhasgas.dldf s sd spukneteilsgavshhifaw ktts o i od ntrri akya hinaeiutei aued bi tdgu se aeharTlit mlnapr cdyrpcrunfurvha wmn lntet

aggelilfpgdo lntw i kpr eyrphiioy ssgsixadL reiad1re vieeot N ta i-nonscGaftud.yProlcndhn, na sLo ru voihrdtN T

L iiga3llle’ o$ihg liv setebn $hhhbssfrief3eejn. oes earads.cvl2rl repi usn,hotmo)gras em. od .io2o5pe2tu1nrnecu'uesn utvfrhoaIww ebysMa lo lw v. n8eoi pt’ate em z tr(Liiisre ,,ocyecrad3lljg nnqti l7ot nue etinuyorlZresapdhhb at i e ednqis,adl riany4t i-leeiluraad0uo f$tn M2ro

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In